We Have Better Obesity Medications, but Access Is Lagging
Obesity experts discuss the cost of newer obesity medications (eg, GLP-1 agonists) and access issues, including Ozempic shortages.
Diagnosis & Disease Information
Maker of Weight-Loss Drug Wegovy Ramps Up Production to Meet Demand
The company expects ‘pent-up demand’ for the Wegovy (semaglutide) to subside within the next few months
Supervised Aerobic Exercise Cuts Long-Term Diabetes Risk With Obesity
One-year moderate, vigorous exercise programs tied to reduction in 10-year risk for diabetes among adults with obesity.
Persistent Gaps Exist in Continuity of Medication Use for Adults With Diabetes
Mean of 19.5%, 17.1%, and 43.3% of participants did not maintain continuity of use of glucose, BP, lipid medications.
Emergency Department Screening Detects Prediabetes, Type 2 Diabetes
Only 25% of patients who were identified self-reported having been diagnosed with prediabetes or type 2 diabetes.
Top January 2023 FDA Approvals
January FDA approvals include treatments for mood disorders, pertussis in infants, Alzheimer disease, and type 2 diabetes.
Total Nitrites Consumption Tied to Higher Type 2 Diabetes Risk
Total nitrates consumption increases a person’s risk of developing type 2 diabetes.
Rybelsus Now First-Line Option for Type 2 Diabetes Following Label Update
Rybelsus is a glucagon-like peptide receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Layered Approach Recommended for Patients With Diabetes, CKD
Layered approach involves initially combining lifestyle interventions, self-management, and first-line pharmacotherapy.
Risk for Type 2 Diabetes Reduced With Higher Daily Step Count
Hazard of incident diabetes reduced by 44% in adjusted models comparing average daily step count of 10,700 to 6000.
- Loading...
Loading...
Next post in Type 2 Diabetes Information Center
Loading... 
Loading...